ATE248157T1 - Verbindungen und verfahren zur modulation von estrogen rezeptoren - Google Patents

Verbindungen und verfahren zur modulation von estrogen rezeptoren

Info

Publication number
ATE248157T1
ATE248157T1 AT99968578T AT99968578T ATE248157T1 AT E248157 T1 ATE248157 T1 AT E248157T1 AT 99968578 T AT99968578 T AT 99968578T AT 99968578 T AT99968578 T AT 99968578T AT E248157 T1 ATE248157 T1 AT E248157T1
Authority
AT
Austria
Prior art keywords
methods
disclosed
compounds
same
modulating
Prior art date
Application number
AT99968578T
Other languages
English (en)
Inventor
Bernd M Stein
David W Anderson
Leah M Gayo
May S Sutherland
Mary Doubleday
Graziella I Shevlin
Adam Kois
Sak Khammungkhune
Ravi Kumar Jalluri
Shripad S Bhagwat
Jeffrey A Mckie
Original Assignee
Signal Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Inc filed Critical Signal Pharm Inc
Application granted granted Critical
Publication of ATE248157T1 publication Critical patent/ATE248157T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
AT99968578T 1998-12-30 1999-12-30 Verbindungen und verfahren zur modulation von estrogen rezeptoren ATE248157T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11447298P 1998-12-30 1998-12-30
PCT/US1999/031290 WO2000039120A2 (en) 1998-12-30 1999-12-30 Compounds and methods for modulation of estrogen receptors

Publications (1)

Publication Number Publication Date
ATE248157T1 true ATE248157T1 (de) 2003-09-15

Family

ID=22355427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968578T ATE248157T1 (de) 1998-12-30 1999-12-30 Verbindungen und verfahren zur modulation von estrogen rezeptoren

Country Status (14)

Country Link
EP (1) EP1140889B1 (de)
JP (1) JP2002533456A (de)
KR (1) KR100615757B1 (de)
CN (2) CN100339374C (de)
AT (1) ATE248157T1 (de)
AU (1) AU765159B2 (de)
CA (1) CA2356986A1 (de)
DE (1) DE69910830T2 (de)
DK (1) DK1140889T3 (de)
ES (1) ES2207982T3 (de)
HK (2) HK1041258B (de)
IL (2) IL144003A0 (de)
PT (1) PT1140889E (de)
WO (1) WO2000039120A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822563B2 (en) 1997-09-22 2004-11-23 Donnelly Corporation Vehicle imaging system with accessory control
US5877897A (en) 1993-02-26 1999-03-02 Donnelly Corporation Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array
US7655894B2 (en) 1996-03-25 2010-02-02 Donnelly Corporation Vehicular image sensing system
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
KR20020075388A (ko) * 1999-12-30 2002-10-04 시그널 파머슈티컬스 인크 에스트로겐 수용체의 조절 화합물 및 조절 방법
EP1177787A3 (de) * 2000-07-28 2003-09-10 Pfizer Products Inc. Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Katarakt
EP1281710A1 (de) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-Benzopyran derivat, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
ATE286894T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
DE60108354T2 (de) * 2001-01-24 2006-01-05 Chiesi Farmaceutici S.P.A. 2H-1-Benzopyranderivate, Verfahren zu ihrer Herstellung und deren pharmazeutische Zusammensetzungen
JP4358515B2 (ja) * 2001-04-10 2009-11-04 タカラバイオ株式会社 治療剤
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
MXPA04010433A (es) * 2002-04-19 2005-08-19 Signal Pharm Inc Compuestos benzopiranona, composiciones de estos y los metodos para el tratamiento con estos.
EP1504276B1 (de) 2002-05-03 2012-08-08 Donnelly Corporation Objektdetektionssystem für ein fahrzeug
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
FR2849653B1 (fr) * 2003-01-08 2006-08-25 B F B Etudes Et Rech S Experim Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant
BRPI0414386A (pt) 2003-09-15 2006-11-21 Signal Pharm Llc composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
US7526103B2 (en) 2004-04-15 2009-04-28 Donnelly Corporation Imaging system for vehicle
EP1846397A1 (de) * 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Neue, als modulatoren der östrogenrezeptoren geeignete heterocyclische benzo[c]chromenderivate
EP1899316A1 (de) * 2005-06-24 2008-03-19 Signal Pharmaceuticals LLC Benzopyranonverbindungen zur behandlung von krebs
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
EP1860104A1 (de) * 2006-05-22 2007-11-28 Aptanomics Von 3-Arylcoumarin oder 3-Arylchinolin-2-on abgeleitete antiproliferative Verbindungen und ihre Verwendung
CN101200460B (zh) * 2007-11-19 2010-06-16 北京珅奥基医药科技有限公司 二氢苯并吡喃酮类化合物及其用途
CN105541810B (zh) * 2016-03-04 2019-05-17 南京工业大学 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用
CN105801544A (zh) * 2016-04-18 2016-07-27 中国药科大学 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801543B (zh) * 2016-04-18 2019-08-02 中国药科大学 4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN112426420B (zh) * 2020-12-01 2021-12-28 浙江大学 香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用
CN112645922B (zh) * 2020-12-24 2022-01-07 中国人民解放军空军军医大学 香豆素类化合物、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857401A (en) * 1956-12-20 1958-10-21 Searle & Co Acetylated coumarin derivatives
DE4323409A1 (de) * 1993-07-13 1995-01-19 Boehringer Mannheim Gmbh Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel
CN1173819A (zh) * 1995-02-06 1998-02-18 伊莱利利公司 抑制il－6作用的方法
JP2001502711A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は治療において有用な新規のシス―３、４―クロマン誘導体
ZA979644B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
EP0937059A1 (de) * 1996-10-28 1999-08-25 Novo Nordisk A/S $i(TRANS)-3,4-CHROMANDERIVATE ZUR VORBEUGUNG ODER BEHANDLUNGVON OESTROGENBEZOGENEN KRANKHEITEN ODER SYNDROMEN
EP0937060B1 (de) * 1996-10-28 2002-12-11 Novo Nordisk A/S Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
JP2001502705A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関係疾患または症候群の予防または治療において有用な新規なシス―３，４―クロマン誘導体
ATE231141T1 (de) * 1996-10-28 2003-02-15 Novo Nordisk As (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen

Also Published As

Publication number Publication date
EP1140889A2 (de) 2001-10-10
WO2000039120A2 (en) 2000-07-06
CN100339374C (zh) 2007-09-26
CN1597677A (zh) 2005-03-23
HK1041258B (zh) 2003-12-12
IL144003A (en) 2006-07-05
WO2000039120A3 (en) 2000-10-26
KR100615757B1 (ko) 2006-08-25
CA2356986A1 (en) 2000-07-06
IL144003A0 (en) 2002-04-21
AU765159B2 (en) 2003-09-11
HK1075893A1 (en) 2005-12-30
PT1140889E (pt) 2004-01-30
CN1155589C (zh) 2004-06-30
JP2002533456A (ja) 2002-10-08
KR20010101346A (ko) 2001-11-14
DE69910830D1 (de) 2003-10-02
ES2207982T3 (es) 2004-06-01
HK1041258A1 (en) 2002-07-05
DE69910830T2 (de) 2004-06-17
EP1140889B1 (de) 2003-08-27
CN1337958A (zh) 2002-02-27
AU2597000A (en) 2000-07-31
DK1140889T3 (da) 2003-12-22

Similar Documents

Publication Publication Date Title
ATE248157T1 (de) Verbindungen und verfahren zur modulation von estrogen rezeptoren
ATE289300T1 (de) Verbindungen und verfahren zur modulation von estrogen rezeptoren
WO2000055137A8 (en) Compounds and methods for modulation of estrogen receptors
MY115784A (en) Estrogen agonists/antagonists
DE69935335D1 (de) Pyrazole als modulatoren des östrogenrezeptors
DE69929345D1 (de) Subtituierte isoxazole derivate als estrogen rezeptor modulatore
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
CY1115317T1 (el) Εκλεκτικος ρυθμιστης οιστρογονικου υποδοχεα σε συνδυασμο με δεϋδροεπιανδροστερονη (dhea) ή αναλογα
AU6045398A (en) Androgen synthesis inhibitors
DE69603827T2 (de) Waisen-rezeptor
ATE292468T1 (de) Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
BR0110087A (pt) Compostos para modular proliferação celular
Chakravatri et al. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer—results from a pilot study
NO984631D0 (no) <alfa>1-Adrenerge reseptor-antagonister
DK1196428T3 (da) 11-beta-aryl-17,17-spirothiolan-substituerede steroider
DK0898708T3 (da) Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays
MY137604A (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
ES2155911T3 (es) Derivados de alcanfor como nuevos odorantes.
Charnock-Jones et al. Vascular endothelial growth factor and corpus luteum angiogenesis
DE69720620D1 (de) 8-Substituierte B-nor-6-Thiaequilin Verbindungen als selektiven Östrogenrezeptormodulatoren
Meyers The role of hormone receptors in estrogen activity is questionable
DE60129892D1 (de) Maus Brustkrebs Zelllinien die Estrogen und Progesteron Rezeptoren exprimieren
Boyde Stereographic visual aids

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140889

Country of ref document: EP

REN Ceased due to non-payment of the annual fee